贝伐单抗联合白蛋白结合型紫杉醇治疗难治三阴性乳腺癌的初步临床观察

为了评价贝伐单抗联合白蛋白结合型紫杉醇治疗晚期难治性三阴性乳腺癌的临床效果,选取经病理学确诊的晚期三阴性乳腺癌患者6例(ER、PR和HER-2均为阴性),既往使用过蒽环、紫杉类、吉西他滨及卡培他滨等药物治疗后进展,接受贝伐单抗联合白蛋白结合型紫杉醇方案治疗,其中贝伐单抗7.5 mg/kg,静脉滴入,d1,3周重复;白蛋白结合型紫杉醇260 mg/m2,静脉滴入,d1,3周重复,不做抗过敏预处理.3例患者接受化疗6个周期,3例4个周期.PR 2例,SD 3例,PD 1倒.毒副反应主要是骨髓抑制和神经毒性,其中Ⅳ度粒细胞减少1例,Ⅲ度粒细胞减少2倒,Ⅱ度粒细胞减少2倒,Ⅰ度粒细胞减少1例；Ⅲ度感觉神经病变2例,Ⅱ度感觉神经病变2例,Ⅰ度感觉神经病变2例；高血压1倒,蛋白尿2例.初步研究结果提示,贝伐单抗联合白蛋白结合型紫杉醇治疗晚期难治性三阴性乳腺癌疗效较好,毒副反应可耐受,值得进一步研究.

Bevacizumab combined with nano albumin paclitaxel for treatment of refractoriness three negative breast cancer

The objective of this study was to evaluate the effectiveness and safety of Bevacizumab combined with nanoparticle albumin-bound paclitaxel for the treatment of metastatic triple negative breast cancer.Bevacizumab plus nanoparticle albumin-bound paclitaxel were administrated to 6 advanced triple-negative breast cancer cases(ER,PR and HER-2 were negative),who were confiemed by histopathology or cytopathology,previously used anthracycline,taxane,gemcitabine and capecitabine and ot her drug treatment after the progress.Bevacizumab 7.5 mg/kg,ivdrip,d1,repeated every 21 days;nanometer albumin paclitaxel 260 mg/m2,ivdrip,d1,repeated every 21 days,without anti-allergy pretreatment.Three patients were accepted 6 cycles of chemotherapy,3 patient 4 cycles.2 patients achieved PR,3 patients SD,1 patient PD.Toxicity is mainly bone marrow suppression and neurotoxicity,The grade 4 neutropenia was took place in 1 patient,The grade 3 neutropenia were took place in 2 patients,the grade 2 neutropenia in 2 patients,the grade 1 neutropenia in 1 patient;the grade 3 neuropathy in 2 patients,the grade 2 neuropathy in 2 patients,the grade 1 neuropathy in 2 patients;hypertension in 1 patient,proteinuria in 2 patients.In conclusion,the combination of Bevacizumab with nanoparticle albumin-bound paclitaxel is an effective and a well-tolerd therapy in patients with metastatic triple negative breast cancer.